CellGF Biomed Technology Co., Ltd.
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
Nucleotide Products, Fluorescent Products, Specialty Nucleotide Products, Enzyme Products, Custom mRNA Synthesis Services, Custom Specialty Nucleotide Services
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2018
Unified Business No.
28114433
Status
Closed
Number of Employees
5
Total Paid-in
Capital
1,255,001 (NT$)
Location of Company
Taiwan
, Taoyuan City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
CellGF Biomed Technology Co., Ltd. is a professional nucleic acid technology research and development company, specializing in mRNA synthesis technology, with the goal of applying mRNA to drug and vaccine development. In recent years, numerous studies have indicated that emerging mRNA therapies, by introducing mRNA molecules into cells, can utilize the body as a production factory to generate drugs that treat its own diseases. They can also be rapidly formulated into vaccines to respond to outbreaks of infectious diseases, and even overcome disease challenges that cannot be resolved by small molecule drugs and protein drugs.
The most critical key to mRNA drug and vaccine development is mastering the "nucleotide-modified mRNA synthesis technology platform (Nucleotide-modified mRNA)." To construct a unique mRNA synthesis platform, CellGF Biomed Technology Co., Ltd. has developed a series of bioprocess technologies to synthesize many key nucleotides, specially modified nucleotides, and enzymes. In addition to bypassing the patent protections of other companies, this significantly reduces the development costs of mRNA drugs and vaccines and enhances mRNA stability, making the company one of the few manufacturers in the world capable of developing high-value special nucleotide raw materials and synthesizing mRNA.
CellGF Biomed Technology Co., Ltd.'s unique bioprocess technology utilizes a series of specific enzymatic reactions without using toxic reagents, thereby providing high-purity nucleotide raw materials that are naturally sourced, stably supplied, non-toxic, and environmentally friendly. In addition to serving as research reagents for molecular diagnostics, because these nucleotide raw materials are produced entirely through bioprocess technology, and because nucleotides themselves possess numerous functions such as promoting cell regeneration, providing energy, and enhancing immunity, their applications can be expanded to skincare products, health supplements, medical devices, and pharmaceuticals. In the future, CellGF Biomed Technology Co., Ltd. will assist domestic and foreign academic and research institutions, as well as novel drug development companies, in producing mRNA drugs and vaccines through customized nucleic acid contract services.
(The content above was translated by AI.)
The most critical key to mRNA drug and vaccine development is mastering the "nucleotide-modified mRNA synthesis technology platform (Nucleotide-modified mRNA)." To construct a unique mRNA synthesis platform, CellGF Biomed Technology Co., Ltd. has developed a series of bioprocess technologies to synthesize many key nucleotides, specially modified nucleotides, and enzymes. In addition to bypassing the patent protections of other companies, this significantly reduces the development costs of mRNA drugs and vaccines and enhances mRNA stability, making the company one of the few manufacturers in the world capable of developing high-value special nucleotide raw materials and synthesizing mRNA.
CellGF Biomed Technology Co., Ltd.'s unique bioprocess technology utilizes a series of specific enzymatic reactions without using toxic reagents, thereby providing high-purity nucleotide raw materials that are naturally sourced, stably supplied, non-toxic, and environmentally friendly. In addition to serving as research reagents for molecular diagnostics, because these nucleotide raw materials are produced entirely through bioprocess technology, and because nucleotides themselves possess numerous functions such as promoting cell regeneration, providing energy, and enhancing immunity, their applications can be expanded to skincare products, health supplements, medical devices, and pharmaceuticals. In the future, CellGF Biomed Technology Co., Ltd. will assist domestic and foreign academic and research institutions, as well as novel drug development companies, in producing mRNA drugs and vaccines through customized nucleic acid contract services.
(The content above was translated by AI.)
